Program
HRS-7172
A development code. Also written as “HRS-7172 + AG + SHR-1316;”, “HRS-7172 + AG + SHR-1316” and “HRS-7172 + AG;”.
Its studies are mostly in Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 22 open or running | phase 2since Sep 2, 2026 | Aug 20, 2025 | Dec 2028phase 1 · NCT07142980 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7172
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2025First study: phase 1 study in Advanced Solid Tumors Harboring RAS Mutations or AmplificationsFirst studyNCT07142980 · 120 planned · China
- Sep 2, 2026Phase 2 study in Pancreatic NeoplasmsPhase 2 reachedNCT07806058 · 140 planned · China
Ahead
- Dec 2028Primary completion: phase 1 study in Advanced Solid Tumors Harboring RAS Mutations or AmplificationsNCT07142980
- Dec 31, 2028Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07806058
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07806058Pancreatic Neoplasms · China | 2 | Recruiting | Dec 31, 2028 | 140 |
| NCT07142980Advanced Solid Tumors Harboring RAS Mutations or Amplifications · China | 1 | Recruiting | Dec 2028 | 120 |
How it is read
Names in the registry
- “HRS-7172 + AG + SHR-1316;”, 2 entries
- “HRS-7172 + AG + SHR-1316”, 1 entry
- “HRS-7172 + AG;”, 1 entry
- “HRS-7172 Tablets”, 1 entry
Codes read as this program: HRS7172.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.